---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-004838"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:35:53.224240+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics reports Halneuron Phase 2b progress, new SP16 license, and 2026 milestones

## Summary
- Over 100 patients enrolled in Halneuron Phase 2b HALT-CINP study; interim analysis determined final sample size and methodology.
- Licensed SP16 IV (royalty-free, global) for cancer neuropathy; Phase 1b fully funded by NCI development grant.
- Developed chemically equivalent synthetic Halneuron for Phase 3; new IP if granted extends protection to 2046.
- Milestones: final Phase 2b data Q3 2026, SP16 IND filing Q1 2026, dosing Phase 1b by mid-2026.
- Completed January financing (undisclosed amount) to fund pipeline; end-of-Phase 2 FDA submission targeted late 2026.

## SEC filing metadata
- accession: 0001104659-26-004838
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000110465926004838/0001104659-26-004838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000110465926004838/dwtx-20260120x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-004838
- JSON: https://secwatch.observer/filing/0001104659-26-004838.json
- Plain text: https://secwatch.observer/filing/0001104659-26-004838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.